Search

Your search keyword '"Bernabé, R."' showing total 43 results

Search Constraints

Start Over You searched for: Author "Bernabé, R." Remove constraint Author: "Bernabé, R." Database ScienceDirect Remove constraint Database: ScienceDirect
43 results on '"Bernabé, R."'

Search Results

3. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

4. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

7. EP.06G.20 Advanced Squamous Cell Lung Carcinoma in Never Smokers: A Different Entity? Analysis from the Thoracic Tumor Registry in Spain (RTT)

10. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

16. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

17. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

18. OA14.01 Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

22. 1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group

23. 1846P - Biomarker testing of lung cancer in Spain

24. 1845P - Tobacco use in lung cancer (LC) patients (p) in Spain

26. 1241P - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients

27. P2.10-02 Smoking Habit in Lung Cancer in Spain

28. P2.05-12 Analysis of Biomarkers in Lung Cancer in Spain

29. P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

30. P2.03-16 Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing

33. OA13.05 NADIM Study: Updated Clinical Research and Outcomes

37. P1.03-054 A Phase II Randomized Trial of Gefitinib Alone vs Olaparib Plus Gegitinib in Advanced NSCLC EGFRmut + Goal Trial Spanish Lung Cancer Group

Catalog

Books, media, physical & digital resources